Oral L-Carnitine Treatment in Hepatic Encephalopathy

Oral L-Carnitine Treatment in Hepatic Encephalopathy - Oral L-Carnitine Stydy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009761

Enrollment

Registered

2013-02-01

Start date

2013-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic encephalopathy

Interventions

Oral L-cartine treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient's age ranges from 20 to 80 years. 2. At least two episodes of overt hepatic encephalopathy (>=Grade 2) associated with hepatic cirrhosis during the previous 6 months, and remission (Grade 0 or 1) at enrollment. 3. Patient's prognosis should be longer than 6 months. 4. In-and Outpatients 5. Patients received document agreement with participation in this study.

Exclusion criteria

Exclusion criteria: 1. Patient's prognosis is shorter than 6 months. 2. Child Pugh grade C 3. Spontaneous bacterial peritonitis 4. Alcoholism or antipsychotic drug user 5. Gastrointestinal hemorrhage 6. The placement of TIPS, B-RTO, or PSE. 7. Patients who judged inappropriate by researcher.

Design outcomes

Primary

Measure	Time frame
The time to the first breakthrough episode of overt hepatic encephalopathy (>=grade 2).	—

Countries

Japan

Contacts

Public ContactYukari Matsumoto

Kurashiki Central Hospital Gastroenterology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026